The nuclear medicine industry has been very active in the recent months which can be highlighted through several key events, confirming the trend announced by MEDraysintell since two years which anticipated an increasing interest from investors and conventional pharmaceutical industries for the nuclear medicine market, mainly in the therapeutic area.

During the month of March 2016, ITM (Isotopen Technologien München) successfully raised EUR 20 million to fund the development of its promising proprietary pipeline of Targeted Radionuclide Therapies; Clarity Pharmaceuticals, an early stage Australian company, has been awarded AU$ 1 million to fund a definitive clinical trial of Cu-64 SARTATE, a neuroendocrine tumors imaging radiopharmaceutical; the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study started to enroll as many as 18,000 patients to determine the clinical usefulness on patient-oriented outcomes of a brain positron emission tomography (PET) scan, using new fluorinated tracers; and IBA successfully completed the sale of IBA Molecular to funds advised by CapVest Partners LP.

In February 2016, inviCRO acquired Molecular NeuroImaging, a company specializing in the application of radiolabeled biomarkers; Ipsen and 3B Pharmaceuticals signed a license agreement to develop novel radiopharmaceuticals; and Bayer published once again strong results for its Xofigo (radium-223 dichloride), a radiotherapeutic used in the treatment of prostate and bone cancers, with sales rising by over 60% in 2015 versus 2014. Last year, the French company Ipsen had already acquired Octreopharm, a German company specialized in the development of radiopharmaceuticals, hence confirming its interest in this area.
In January 2016, IBA Molecular North America, a manufacturer and distributor of radiopharmaceuticals, was renamed Zevacor Pharma, Inc., following the acquisition made by mid-2015, and Advanced Accelerator Applications SA acquired the IDB Group, The Netherlands, a producer of Lutetium 177.

By end of 2015, FACIT invested in Fusion Pharmaceuticals to support the development of alpha particle-emitting radiotherapeutics.

The global nuclear medicine industry is evaluated in a MEDraysintell's report and directory, providing in a 930-page document a complete description of over 335 radiopharmaceuticals and radionuclides and more than 160 companies and institutions active in this field around the world. http://medraysintell.com/Nuclear_Medicine.html

Market Analysis Homepage